The wrong prescription for drug affordability
Summary
The Medication Affordability and Patent Integrity Act proposes new rules for biotech companies. These rules could slow down the development of new medicines but are not expected to reduce the cost of prescription drugs.Key Facts
- The act aims to regulate biotech companies more strictly.
- It would add new requirements and delays to developing treatments.
- The law targets the process of creating new medicines.
- It does not include measures to lower drug prices.
- Biotech companies could face greater challenges meeting the rules.
- The goal of lowering prescription drug costs is not addressed by this act.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.